Pitobrutinib/Pitobrutinib (Zepali) generally requires several courses of treatment to be effective

Pitobrutinib/Pirtobrutinib (Pirtobrutinib) is a new type of non-covalent BTK inhibitor, mainly used to treat relapsed or refractory lymphoma derived from B cells. Its pharmacological mechanism selectively inhibits the BTK signaling pathway and blocks B cell receptor signals, thereby inhibiting tumor cell proliferation and promoting apoptosis. Since its effect is based on continuous inhibition of signaling pathways, the emergence of therapeutic effects often requires cumulative administration over a certain period of time, rather than producing obvious effects immediately.

Clinical research data show that most patients can observe signs of improvement in hematological indicators or shrinkage of some lesions on imaging within a few weeks to two or three months after starting to take pitubrutinib. Generally speaking, the initial efficacy evaluation is usually scheduled from 8 to 12 weeks after medication, and the early response to the drug is judged through blood routine, lymph node size, and changes in tumor markers. Some patients may experience significant relief within a shorter period of time, while patients with higher drug resistance or faster disease progression may require a longer course of treatment to observe the effect.

For the maintenance of long-term efficacy, the regimen of pitubrutinib is usually recommended to be continued until disease progression or intolerable adverse reactions occur. The number of treatment courses is not fixed, but is based on the patient's disease control. In other words, even if the initial course of treatment shows partial response, the medication still needs to be maintained to consolidate the effect and avoid disease recurrence or progression.

Patients should be closely followed up during the period of taking it, including blood routine, tumor burden and adverse reaction monitoring. Efficacy assessment combines imaging and clinical symptoms to help doctors decide whether to continue the current course of treatment or adjust the dose. At the same time, patience and regular long-term medication are crucial to achieve optimal treatment results. For most patients, stable and sustainable efficacy of pitubrutinib is usually observed after several courses of treatment.

Keyword tags: Pitobrutinib, course of treatment, efficacy evaluation, long-term maintenance, disease control

Reference:https://en.wikipedia.org/wiki/Pirtobrutinib